Characteristics and Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab Combination Therapy Who Achieved Complete Response
Achieving CR by mRECIST using Atz/Bev alone or with additional TACE can be expected to offer an extremely favorable prognosis.
Authors
- Yoshihiko Tachi (ORCID: https://orcid.org/0000-0001-9799-2445)
- Kohei Funasaka (ORCID: https://orcid.org/0000-0002-3869-1420)
- Eizaburo Ohno (ORCID: https://orcid.org/0000-0002-7730-4630)
- Teiji Kuzuya (ORCID: https://orcid.org/0000-0002-2229-990X)
- Ryoji Miyahara (ORCID: https://orcid.org/0000-0001-7172-4602)
- Kazunori Nakaoka (ORCID: https://orcid.org/0000-0002-7407-1763)
- Naoto Kawabe (ORCID: https://orcid.org/0000-0002-4582-0868)
- Yoshiki Hirooka (ORCID: https://orcid.org/0000-0001-9639-7425)
- Takuji Nakano (ORCID: https://orcid.org/0000-0001-9914-3033)
- Hisanori Muto (ORCID: https://orcid.org/0000-0003-2121-2494)
- Hiroyuki Tanaka (ORCID: https://orcid.org/0000-0003-2306-0842)
- Mitsuo Nagasaka (ORCID: https://orcid.org/0000-0003-2099-6143)
- Gakushi Komura
- Takeshi Ukai
- Yuryo Wada
Institutions
- Fujita Health University (JP)
- Fujita Health University Hospital (JP)
- Fujita Health University Okazaki Medical Center
- Fujita Health University Bantane Hospital
Publication Details
- Journal
- Current Oncology
- Published
- 2024-10-16
- DOI
- https://doi.org/10.3390/curroncol31100463
- Citations
- 6
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.22